Towa Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4553.T

Towa Pharmaceutical Co., Ltd. Capital Expenditure for the year ending March 31, 2024: USD -259.82 M

Towa Pharmaceutical Co., Ltd. Capital Expenditure is USD -259.82 M for the year ending March 31, 2024, a -13.29% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Towa Pharmaceutical Co., Ltd. Capital Expenditure for the year ending March 31, 2023 was USD -229.34 M, a -105.64% change year over year.
Towa Pharmaceutical Co., Ltd. Capital Expenditure for the year ending March 31, 2022 was USD -111.53 M, a -25.02% change year over year.
Towa Pharmaceutical Co., Ltd. Capital Expenditure for the year ending March 31, 2021 was USD -89.21 M, a -105.42% change year over year.
Towa Pharmaceutical Co., Ltd. Capital Expenditure for the year ending March 31, 2020 was USD -43.43 M, a 57.59% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Tokyo Stock Exchange: 4553.T

Towa Pharmaceutical Co., Ltd.

CEO	Mr. Itsuro Yoshida
IPO Date	April 5, 2004
Location	Japan
Headquarters	2-11, Shinbashi-cho
Employees	4,588
Sector	Health Care
Industries Pharmaceuticals

Description

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Key trends

Past 5 years